REJUVXL

REJUVXL™ is a ready-to-administer cell therapy derived from perinatal tissues that are usually discarded after delivery of healthy newborn babies. A scalable, robust manufacturing platform allows production of thousands of therapeutic cell doses that can be administered through a simple intravascular infusion (similar to a blood transfusion) and do not require anti-rejection drugs (immunosuppression) treatment of the recipients. These cell products represent the youngest source of cells that can be obtained after birth, eliminating the need for embryonic or fetal cell products, and their associated risks.

Possible mechanisms of action include:

• Reduction of inflammation and fibrosis
• Modulation of the immune system
• Promotion of angiogenesis and tissue regeneration

Optimized for chronic inflammatory and degenerative diseases, REJUVXL™ is first being evaluated for CKD, with potential expansion into additional indications.

Expanding the REJUVXL™ Pipeline

The CKD trial is a key step in AION Healthspan’s broader mission to develop regenerative therapies for multiple degenerative diseases. Alongside this trial, AION Healthspan is advancing a combination therapy approach for graft-versus-host disease (GvHD), with the first patient already treated at Stanford University. These efforts reinforce AION Healthspan’s commitment to pioneering transformative treatments to restore health and extend healthspan.